Diagnosis and management of non-infectious immune-mediated scleritis: current status and future prospects

References

• Okhravi N, Odufuwa B, McCluskey P, et al. Scleritis. Surv Ophthalmol. 2005;50:351–363.
   PubMed Web of Science ®Google Scholar
• Raiji VR, Palestine AG, Parver DL. Scleritis and systemic disease association in a community-based referral practice. Am J Ophthalmol. 2009;148:946–950.
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119:43–50.
   PubMed Web of Science ®Google Scholar
• Erkanli L, Akova YA, Guney-Tefekli E, et al. Clinical features, prognosis, and treatment results of patients with scleritis from 2 tertiary eye care centers in Turkey. Cornea. 2010;29:26–33.
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101:389–396.
   PubMed Web of Science ®Google Scholar
• Tuft SJ, Watson PG. Progression of scleral disease. Ophthalmology. 1991;98:467–471.
   PubMed Web of Science ®Google Scholar
• Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60:163–191.
   PubMed Web of Science ®Google Scholar
• Watson PG. Doyne memorial lecture, 1982. The nature and the treatment of scleral inflammation. Trans Ophthalmol Soc UK. 1982;102:257–281.
   PubMedGoogle Scholar
• Watson PG. Treatment of scleritis and episcleritis. Trans Ophthalmol Soc UK. 1974;94:76–79.
   Google Scholar
• Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol. 2007;3:219–226.
   PubMedGoogle Scholar
• Sainz de la Maza M, Foster CS, Jabbur NS, et al. Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy. Arch Ophthalmol. 2002;120:15–19.
   PubMedGoogle Scholar
• Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102:687–692.
   PubMed Web of Science ®Google Scholar
• Hodson KL, Galor A, Karp CL, et al. Epidemiology and visual outcomes in patients with infectious scleritis. Cornea. 2013;32:466–472.
   PubMed Web of Science ®Google Scholar
• Jain V, Garg P, Sharma S. Microbial scleritis experience from a developing country. Eye (Lond). 2009;23:255–261.
   PubMed Web of Science ®Google Scholar
• Ramenaden ER, Raiji VR. Clinical characteristics and visual outcomes in infectious scleritis: a review. Clin Ophthalmol. 2013;7:2113–2122.
   PubMedGoogle Scholar
• Mushtaq B, Kumar V, Saeed T, et al. Self-inflicted anterior scleritis. Eye (Lond). 2003;17:107–108.
   PubMed Web of Science ®Google Scholar
• Riono WP, Hidayat AA, Rao NA. Scleritis: a clinicopathologic study of 55 cases. Ophthalmology. 1999;106:1328–1333.
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M. Scleritis immunopathology and therapy. Dev Ophthalmol. 1999;30:84–90.
   PubMedGoogle Scholar
• Di Girolamo N, Lloyd A, McCluskey P, et al. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol. 1997;150:653–666.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Di Girolamo N, Thurau S, et al. Scleritis: immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res. 2013;35:44–62.
   PubMed Web of Science ®Google Scholar
• Fong LP, Sainz de la Maza M, Rice BA, et al. Immunopathology of scleritis. Ophthalmology. 1991;98:472–479.
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Tauber J, Foster CS. The sclera. New York: Springer-Verlag; 2012.
   Google Scholar
• Tuft SJ, Watson PG. Progression of scleral disease. Ophthalmology. 1991;98:467–471.
   PubMed Web of Science ®Google Scholar
• Benson WE. Posterior scleritis. Surv Ophthalmol. 1988;32:297–316.
   PubMed Web of Science ®Google Scholar
• McCluskey PJ, Watson PG, Lightman S, et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999;106:2380–2386.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT, Watson PG. Evaluation of eyes enucleated for scleritis. Br J Ophthalmol. 1976;60:227–230.
   PubMed Web of Science ®Google Scholar
• Castells DD. Anterior scleritis: three case reports and a review of the literature. Optometry. 2004;75:430–444.
   PubMedGoogle Scholar
• Lin P, Bhullar SS, Tessler HH, et al. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol. 2008;145:463–471.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Thorne JE, Qazi FA, et al. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111:501–506.
   PubMed Web of Science ®Google Scholar
• Biswas J, Mittal S, Ganesh SK, et al. Posterior scleritis: clinical profile and imaging characteristics. Indian J Ophthalmol. 1998;46:195–202.
   PubMedGoogle Scholar
• Cordero-Coma M, Garcia-Moran A, Yilmaz T, et al. Adjunctive globe magnetic resonance imaging in the diagnosis of posterior scleritis. Can J Ophthalmol. 2011;46:329–332.
   PubMed Web of Science ®Google Scholar
• Li CQ, Cho AA, Edward NJ, et al. Magnetic resonance imaging of uveitis. Neuroradiology. 2015;57:825–832.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Schilling M, Lung E, et al. Ultrasound biomicroscopy in scleritis. Ophthalmology. 1998;105:527–534.
   PubMed Web of Science ®Google Scholar
• Shoughy SS, Jaroudi MO, Kozak I, et al. OCT in the diagnosis of scleritis and episcleritis. Am J Ophthalmol. 2015;159:1045–1049.
   PubMed Web of Science ®Google Scholar
• Taki W, Keino H, Watanabe T, et al. Enhanced depth imaging optical coherence tomography of the choroid in recurrent unilateral posterior scleritis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1003–1004.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuizen J, Watson PG, Emmanouilidis-van der Spek K, et al. The value of combining anterior segment fluorescein angiography with indocyanine green angiography in scleral inflammation. Ophthalmology. 2003;110:1653–1666.
   PubMed Web of Science ®Google Scholar
• Roufas A, Jalaludin B, Gaskin C, et al. Subconjunctival triamcinolone treatment for non-necrotising anterior scleritis. Br J Ophthalmol. 2010;94:743–747.
   PubMed Web of Science ®Google Scholar
• Sohn EH, Wang R, Read R, et al. Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology. 2011;118:1932–1937.
   PubMed Web of Science ®Google Scholar
• Albini TA, Rao NA, Smith RE. The diagnosis and management of anterior scleritis. Int Ophthalmol Clin. 2005;45:191–204.
   PubMedGoogle Scholar
• Beardsley RM, Suhler EB, Rosenbaum JT, et al. Pharmacotherapy of scleritis: current Paradigms and future directions. Expert Opin Pharmacother. 2013;14:411–424.
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Scleritis therapy. Ophthalmology. 2012;119:51–58.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Robertson JE Jr. Recognition of posterior scleritis and its treatment with indomethacin. Retina. 1993;13:17–21.
   PubMed Web of Science ®Google Scholar
• Nascimento H, Franca M, Garcia LG, et al. Subconjunctival dexamethasone implant for non-necrotizing scleritis. J Opthalmic Inflamm Infect. 2013;3:7.
   PubMedGoogle Scholar
• Jabs DA, Mudun A, Dunn JP, et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469–476.
   PubMed Web of Science ®Google Scholar
• Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266–273.
   PubMedGoogle Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Systemic immunosuppressive therapy for eye diseases cohort study. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–2198.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–1139.
   PubMed Web of Science ®Google Scholar
• Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11:131–139.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362–365.
   PubMed Web of Science ®Google Scholar
• Jachens AW, Chu DS. Retrospective review of methotrexate therapy in the treatment of chronic, noninfectious, nonnecrotizing scleritis. Am J Ophthalmol. 2008;145:487–492.
   PubMed Web of Science ®Google Scholar
• Mellado F, Talesnik E, Castiglione E. Azathioprine as monotherapy for scleritis in relapsing polychondritis. Ocul Immunol Inflamm. 2012;20:235–236.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–509.
   PubMed Web of Science ®Google Scholar
• Sen HN, Suhler EB, Al-Khatib SQ, et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology. 2003;110:1750–1755.
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423–432.
   PubMed Web of Science ®Google Scholar
• Kolomeyer AM, Ragam A, Shah K, et al. Mycophenolate mofetil in the treatment of chronic non-infectious, non-necrotizing scleritis. Ocul Immunol Inflamm. 2012;20:113–118.
   PubMed Web of Science ®Google Scholar
• Langford CA, Talar-Williams C, Barron KS, et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114:463–469.
   PubMed Web of Science ®Google Scholar
• Stone JH. Polyarteritis nodosa. JAMA. 2002;288:1632–1639.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109:370–377.
   PubMed Web of Science ®Google Scholar
• McCarthy JM, Dubord PJ, Chalmers A, et al. Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol. 1992;19:1358–1361.
   PubMed Web of Science ®Google Scholar
• Aoki H, Hiraoka M, Hashimoto M, et al. Systemic cyclosporine therapy for scleritis: a proposal of a novel system to assess the activity of scleritis. Case Rep Ophthalmol. 2015;6:149–157.
   PubMedGoogle Scholar
• Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576–584.
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Masuda K, Sakane T, et al., et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115:763–769.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123:634–641.
   PubMed Web of Science ®Google Scholar
• Young AL, Wong SM, Leung AT, et al. Successful treatment of surgically induced necrotizing scleritis with tacrolimus. Clin Experiment Ophthalmol. 2005;33:98–99.
   PubMed Web of Science ®Google Scholar
• Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet’s disease. Ocul Immunol Inflamm. 2012;20:198–202.
   PubMed Web of Science ®Google Scholar
• Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895–900.
   PubMed Web of Science ®Google Scholar
• Sen HN, Sangave A, Hammel K, et al. Infliximab for the treatment of active scleritis. Can J Ophthalmol. 2009;44:9–12.
   PubMedGoogle Scholar
• Doctor P, Sultan A, Syed S, et al. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94:579–583.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127:819–822.
   PubMed Web of Science ®Google Scholar
• Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol. 2011;4:139–141.
   PubMedGoogle Scholar
• Ragam A, Kolomeyer AM, Fang C, et al. Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. Ocul Immunol Inflamm. 2014;22:469–477.
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol. 2012;39:233–239.
   PubMed Web of Science ®Google Scholar
• Hernandez-Illas M, Tozman E, Fulcher SF, et al. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens. 2004;30:2–5.
   PubMedGoogle Scholar
• Tlucek PS, Stone DU. Certolizumab pegol-therapy for rheumatoid arthritis associated scleritis. Cornea. 2012;31:90–91.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G. Rituximab for noninfectious uveitis. Dev Ophthalmol. 2012;51:98–109.
   PubMedGoogle Scholar
• Bogdanic-Werner K, Fernandez-Sanz G, Alejandre Alba N, et al. Rituximab therapy for refractory idiopathic scleritis. Ocul Immunol Inflamm. 2013;21:329–332.
   PubMed Web of Science ®Google Scholar
• Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861–869.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121:1885–1891.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm. 2008;16:230–232.
   PubMed Web of Science ®Google Scholar
• Foster CS, Kothari S, Anesi SD, et al. The Ocular Immunology and Uveitis Foundation (OIUF) preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;1:1–16. doi:10.1016/j.survophthal.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Cao JH, Oray M, Cocho L, et al. Rituximab in the treatment of refractory non-infectious scleritis. Am J Ophthalmol. 2016;164:22–28. doi:10.1016/j.ajo.2015.12.032.
   PubMed Web of Science ®Google Scholar
• Tode J, Zeuner R, Saeger M, et al. Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis. Acta Ophthalmol. 2015 [Jun 1];93:e683-e684. doi:10.1111/aos.12720. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenc V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121:2380–2386.
   PubMed Web of Science ®Google Scholar
• Adan A, Mesquida M, Llorenc V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32:75–79.
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso S, Ostuni PA, et al. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology. 2007;46:1042–1043.
   PubMed Web of Science ®Google Scholar
• Bhatt N, Dalal M, Tucker W, et al. Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I:II clinical trial. Am J Ophthalmol. 2015;159:601–606.
   PubMed Web of Science ®Google Scholar
• McCluskey P, Wakefield D. Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol. 1995;19:211–215.
   Google Scholar
• Sen HN, Sangave AA, Goldstein DA, et al. A standardized grading system for scleritis. Ophthalmology. 2011;118:768–771.
   PubMed Web of Science ®Google Scholar